search
Back to results

Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males

Primary Purpose

Hypotension, Spinal Cord Injury

Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
tadalafil
placebo
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypotension focused on measuring Hypotension in SCI males, Erectile Dysfunction

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • males 18 to 70 years old, with complete spinal cord injury (ASIA-A) between C-4 and T-6
  • minimum 6 months post-injury

Exclusion Criteria:

  • diabetic
  • taking nitroglycerin
  • ischemic heart disease or significantly abnormal EKG
  • lower motor neuron dysfunction
  • heroin or cocaine use
  • history of adverse reaction to tadalafil or any other PDE-5 inhibitor
  • any condition that may put the subject at risk, confound the study results, or interfere significantly with subject's ability to participate in the study
  • have used any other (PDE-5) medications within 1 week of study medication administration

Sites / Locations

  • Health Sciences Centre Rehabilitation Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

tadalafil 20 mg

placebo

Arm Description

Oral study medication to be administered once to each participant

oral study medication to be administered once to each study participant

Outcomes

Primary Outcome Measures

Supine and sitting blood pressure and heart rate (HR), as well as perceived dizziness upon sitting up.

Secondary Outcome Measures

Full Information

First Posted
February 10, 2010
Last Updated
July 16, 2015
Sponsor
University of Manitoba
Collaborators
Manitoba Medical Service Foundation, Rick Hansen Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01067391
Brief Title
Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males
Official Title
A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Manitoba
Collaborators
Manitoba Medical Service Foundation, Rick Hansen Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To address the effect of tadalafil (Cialis) on the cardiovascular system of men with complete spinal cord injury at T-6 and above. The hypothesis is that tadalafil will cause significant hypotension in people with tetraplegia.
Detailed Description
Tadalafil is a long-acting PDE-5 inhibitor, used to treat erectile dysfunction (ED). ED is a common issue for males with spinal cord injury (SCI).Patients with SCI are at risk of developing orthostatic hypotension, especially those with an injury at or above the T-6 level.An earlier study of the shorter-acting PDE-5 inhibitor sildenafil (Viagra) revealed that it can cause orthostatic hypotension, tachycardia and dizziness after administration in the SCI population, and suggested that caution should be used in prescribing sildenafil in this population, as blood pressure can drop significantly. There is potential for the significant hypotension seen with the short-acting medications to be much more problematic with the longer-acting tadalafil. The study will be a prospective, randomized, double-blind, placebo-controlled cross-over design. This will be done by comparing the effects of administering tadalafil 20 mg and placebo on blood pressure (lying and sitting), and heart rate (lying and sitting). These measurements will be taken in the clinic setting prior to dosing, then repeated hourly for the first two hours post-dose, and again at four hours post-dose. The patient will repeat the measurements at home using an automated blood pressure apparatus at 12, 22,29 and 36 hours post-dose.In addition, the patient will record perceived dizziness on a visual analog scale ecah time the BP and HR are recorded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension, Spinal Cord Injury
Keywords
Hypotension in SCI males, Erectile Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
tadalafil 20 mg
Arm Type
Active Comparator
Arm Description
Oral study medication to be administered once to each participant
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
oral study medication to be administered once to each study participant
Intervention Type
Drug
Intervention Name(s)
tadalafil
Other Intervention Name(s)
Cialis
Intervention Description
20 mg tablet, administered once per study protocol
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo tablet administered once per study protocol
Primary Outcome Measure Information:
Title
Supine and sitting blood pressure and heart rate (HR), as well as perceived dizziness upon sitting up.
Time Frame
Pre-dose, 1 hour, 2, 4, 12, 22, 29 and 36 hours post-dose.

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: males 18 to 70 years old, with complete spinal cord injury (ASIA-A) between C-4 and T-6 minimum 6 months post-injury Exclusion Criteria: diabetic taking nitroglycerin ischemic heart disease or significantly abnormal EKG lower motor neuron dysfunction heroin or cocaine use history of adverse reaction to tadalafil or any other PDE-5 inhibitor any condition that may put the subject at risk, confound the study results, or interfere significantly with subject's ability to participate in the study have used any other (PDE-5) medications within 1 week of study medication administration
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen D. Ethans, MD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Health Sciences Centre Rehabilitation Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1M4
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males

We'll reach out to this number within 24 hrs